specialty [2%:<1%) renal clearance. In a clinical study of subjects with mild, moderate, severe or end stage (dialysis-dependent) renal insufficiency, anidulafungin pharmacokinetics were similar to those observed in subjects with normal renal function. Anidulafungin is not dialyzable and may be administered without regard to the timing of hemodialysis [ see Clinical Pharmacology (12.4) ]. Overdosage During clinical trials a single 400 mg dose of Eraxis was inadvertently administered as a loading dose. No clinical adverse events were reported. In a study of 10 healthy subjects administered a loading dose of 260 mg followed by 130 mg daily, Eraxis was generally well tolerated; 3 of the 10 subjects experienced transient, asymptomatic transaminase elevations ( 3 x ULN) [ see Warnings and Precautions (5.1) ]. Anidulafungin is not dialyzable. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50 mg/day) or equivalent to 5 times the recommended daily dose for candidemia and other Candida infections (100 mg/day), based on relative body surface area comparisons. Eraxis Description Eraxis for Injection is a sterile, lyophilized product for intravenous (IV) infusion that contains anidulafungin. Eraxis (anidulafungin) is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans . Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. Eraxis (anidulafungin) is 1-[(4R,5R)-4,5-dihydroxy-N 2 -[[4"-(pentyloxy)[1,1':4',1"-terphenyl]-4-yl]carbonyl]-L-ornithine]echinocandin B. Anidulafungin is a white to off-white powder that is practically insoluble in water and slightly soluble in ethanol. In addition to the active ingredient, anidulafungin, Eraxis for Injection contains the following inactive ingredients: 50 mg/vial - fructose (50 mg), mannitol (250 mg), polysorbate 80 (125 mg), tartaric acid (5.6 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment. 100 mg/vial - fructose (100 mg), mannitol (500 mg), polysorbate 80 (250 mg), tartaric acid (11.2 mg), and sodium hydroxide and/or hydrochloric acid for pH adjustment. The empirical formula of anidulafungin is C 58 H 73 N 7 O 17 and the formula weight is 1140.3. The structural formula is: Prior to administration, Eraxis for Injection requires reconstitution with sterile Water for Injection and subsequent dilution with either 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (normal saline). DO NOT dilute with other solutions or co-infuse with other medications or electrolytes [ see Dosage and Administration (2) ] . Eraxis - Clinical Pharmacology Mechanism of Action Anidulafungin is an anti-fungal drug [ see Microbiology (12.4) ] . Pharmacokinetics General Pharmacokinetic Characteristics The pharmacokinetics of anidulafungin following intravenous (IV) administration have been characterized in healthy subjects, special populations and patients. Systemic exposures of anidulafungin are dose-proportional and have low intersubject variability (coefficient of variation> <25%) as shown in Table 4. The steady state was achieved on the first day after a loading dose (twice the daily maintenance dose) and the estimated plasma accumulation factor at steady state is approximately 2. Table 4: Mean (%CV) Steady State Pharmacokinetic Parameters of Anidulafungin Following IV Administration of Anidulafungin Once Daily for 10 Days in Healthy Adult Subjects PK Parameter * Anidulafungin IV Dosing Regimen (LD/MD, mg) † 70/35 ‡ , (N=6) 200/100 (N=10) 260/130 , (N=10) C max, ss = the steady state peak concentration AUC ss = the steady state area under concentration vs. time curve CL = clearance t 1/2 = the terminal elimination half-life * Parameters were obtained from separate studies † LD/MD: loading dose/maintenance dose once daily ‡ Data were collected on Day 7 Safety and efficacy of these doses has not been established See OVERDOSAGE C max, ss [mg/L] 3.55 (13.2) 8.6 (16.2) 10.9 (11.7) AUC ss [mg h/L] 42.3 (14.5) 111.8 (24.9) 168.9 (10.8) CL [L/h] 0.84 (13.5) 0.94 (24.0) 0.78 (11.3) t 1/2 [h] 43.2 (17.7) 52.0 (11.7) 50.3 (9.7) The clearance of anidulafungin is about 1 L/h and anidulafungin has a terminal elimination half-life of 40 50 hours. Distribution The pharmacokinetics of anidulafungin following IV administration are characterized by a short distribution half-life (0.5 1 hour) and a volume of distribution of 30 50 L that is similar to total body fluid volume. Anidulafungin is extensively bound (>99%) to human plasma proteins. Metabolism Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) isoenzymes. It is unlikely that anidulafungin will have clinically relevant effects on the metabolism of drugs metabolized by CYP450 isoenzymes. Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity. The in vitro degradation half-life of anidulafungin under physiologic conditions is about 24 hours. In vivo , the ring-opened product is subsequently converted to peptidic degradants and eliminated. Excretion In a single-dose clinical study, radiolabeled ( 14 C) anidulafungin was administered to healthy subjects. Approximately 30% of the administered radioactive dose was eliminated in the feces over 9 days, of which less than 10% was intact drug. Less than 1% of the administered radioactive dose was excreted in the urine. Anidulafungin concentrations fell below the lower limits of quantitation 6 days post-dose. Negligible amounts of drug-derived radioactivity were recovered in blood, urine, and feces 8 weeks post-dose. Specific Populations Patients with fungal infections Population pharmacokinetic analyses from four clinical trials including 107 male and 118 female patients with fungal infections showed that the pharmacokinetic parameters of anidulafungin are not affected by age, race, or the presence of concomitant medications which are known metabolic substrates, inhibitors or inducers. The pharmacokinetics of anidulafungin in patients with fungal infections are similar to those observed in healthy subjects. The pharmacokinetic parameters of anidulafungin estimated using population pharmacokinetic modeling following IV administration of a maintenance dose of 50 mg/day or 100 mg/day (following a loading dose) are presented in Table 5. Table 5: Mean (%CV) Steady State Pharmacokinetic Parameters of Anidulafungin Following IV Administration of Anidulafungin in Patients with Fungal Infections Estimated Using Population Pharmacokinetic Modeling PK Parameter * Anidulafungin IV Dosing Regimen (LD/MD, mg) † 100/50 200/100 * All the parameters were estimated by population modeling using a two-compartment model with first order elimination; AUC ss , C max,ss and C min,ss (steady state trough plasma concentration) were estimated using individual PK parameters and infusion rate of 1 mg/min to administer recommended doses of 50 and 100 mg/day. † LD/MD: loading dose/daily maintenance dose ‡ t 1/2, β is the predominant elimination half-life that characterizes the majority of the concentration-time profile. C max, ss [mg/L] 4.2 (22.4) 7.2 (23.3) C min, ss [mg/L] 1.6 (42.1) 3.3 (41.8) AUC ss [mg h/L] 55.2 (32.5) 110.3 (32.5) CL [L/h] 1.0 (33.5) t 1/2, β [h] ‡ 26.5 (28.5) Gender Dosage adjustments are not required based on gender. Plasma concentrations of anidulafungin in healthy men and women were similar. In multiple-dose patient studies, drug clearance was slightly faster (approximately 22%) in men. Geriatric Dosage adjustments are not required for geriatric patients. The population pharmacokinetic analysis showed that median clearance differed slightly between the elderly group (patients ≥65, median CL=1.07 L/h) and the non-elderly group (patients> <65, median CL=1.22 L/h) and the range of clearance was similar. Race Dosage adjustments are not required based on race. Anidulafungin pharmacokinetics were similar among Whites, Blacks, Asians, and Hispanics. HIV Status Dosage adjustments are not required based on HIV status, irrespective of concomitant anti-retroviral therapy. Hepatic Insufficiency Dosage adjustments are not required on the basis of mild, moderate or severe hepatic insufficiency. Anidulafungin is not hepatically metabolized. Anidulafungin pharmacokinetics were examined in subjects with Child-Pugh class A, B or C hepatic insufficiency. Anidulafungin concentrations were not increased in subjects with any degree of hepatic insufficiency. Though a slight decrease in AUC was observed in patients with Child-Pugh C hepatic insufficiency, it was within the range of population estimates noted for healthy subjects. Renal Insufficiency Dosage adjustments are not required for patients with any degree of renal insufficiency including those on hemodialysis. Anidulafungin has negligible renal clearance. In a clinical study of subjects with mild, moderate, severe or end stage (dialysis-dependent) renal insufficiency, anidulafungin pharmacokinetics were similar to those observed in subjects with normal renal function. Anidulafungin is not dialyzable and may be administered without regard to the timing of hemodialysis. Pediatric The pharmacokinetics of anidulafungin after daily doses were investigated in immunocompromised pediatric (2 through 11 years) and adolescent (12 through 17 years) patients with neutropenia. The steady state was achieved on the first day after administration of the loading dose (twice the maintenance dose), and the C max and AUC ss increased in a dose-proportional manner. Concentrations and exposures following administration of maintenance doses of 0.75 and 1.5 mg/kg/day in this population were similar to those observed in adults following maintenance doses of 50 and 100 mg/day, respectively (as shown in Table 6) . Table 6: Mean (%CV) Steady State Pharmacokinetic Parameters of Anidulafungin Following IV Administration of Anidulafungin Once Daily in Pediatric Subjects PK Parameter * Anidulafungin IV Dosing Regimen (LD/MD, mg/kg) † 1.5/0.75 3.0/1.5 * Data were collected on Day 5 † LD/MD: loading dose/daily maintenance dose ‡ Safety and effectiveness has not been established in pediatric patients 16 years of age Age Group ‡ 2 11 years (N = 6) 12 17 years (N = 6) 2 11 years (N = 6) 12 17 years (N = 6) C max, ss [mg/L] 3.32 (50.0) 4.35 (22.5) 7.57 (34.2) 6.88 (24.3) AUC ss [mg h/L] 41.1 (38.4) 56.2 (27.8) 96.1 (39.5) 102.9 (28.2) Drug Interactions In vitro studies showed that anidulafungin is not metabolized by human cytochrome P450 or by isolated human hepatocytes, and does not significantly inhibit the activities of human CYP isoforms (1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A) in clinically relevant concentrations. No clinically relevant drug-drug interactions were observed with drugs likely to be co-administered with anidulafungin. Cyclosporine (CYP3A4 substrate) In a study in which 12 healthy adult subjects received 100 mg/day maintenance dose of anidulafungin following a 200 mg loading dose (on Days 1 to 8) and in combination with 1.25 mg/kg oral cyclosporine twice daily (on Days 5 to 8), the steady state C max of anidulafungin was not significantly altered by cyclosporine; the steady state AUC of anidulafungin was increased by 22%. A separate in vitro study showed that anidulafungin has no effect on the metabolism of cyclosporine. No dosage adjustment of either drug is warranted when co-administered [ see Drug Interactions (7.1) ] . Voriconazole (CYP2C19, CYP2C9, CYP3A4 inhibitor and substrate) In a study in which 17 healthy subjects received 100 mg/day maintenance dose of anidulafungin following a 200 mg loading dose, 200 mg twice daily oral voriconazole (following two 400 mg loading doses) and both in combination, the steady state C max and AUC of anidulafungin and voriconazole were not significantly altered by co-administration. No dosage adjustment of either drug is warranted when co-administered [ see Drug Interactions (7.2) ] . Tacrolimus (CYP3A4 substrate) In a study in which 35 healthy subjects received a single oral dose of 5 mg tacrolimus (on Day 1), 100 mg/day maintenance dose of anidulafungin following a 200 mg loading dose (on Days 4 to 12) and both in combination (on Day 13), the steady state C max and AUC of anidulafungin and tacrolimus were not significantly altered by co-administration. No dosage adjustment of either drug is warranted when co-administered [ see Drug Interactions (7.3) ] . Rifampin (potent CYP450 inducer) The pharmacokinetics of anidulafungin were examined in 27 patients that were co-administered anidulafungin and rifampin. The population pharmacokinetic analysis showed that when compared to data from patients that did not receive rifampin, the pharmacokinetics of anidulafungin were not significantly altered by co-administration with rifampin. No dosage adjustment of anidulafungin is warranted [ see Drug Interactions (7.4) ] . Amphotericin B liposome for injection The pharmacokinetics of anidulafungin were examined in 27 patients that were co-administered liposomal amphotericin B. The population pharmacokinetic analysis showed that when compared to data from patients that did not receive amphotericin B, the pharmacokinetics of anidulafungin were not significantly altered by co-administration with amphotericin B. No dosage adjustment of anidulafungin is warranted [ see Drug Interactions (7.5) ] . Microbiology Mechanism of Action Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall. Activity in vitro Anidulafungin has been shown to be active against Candida albicans , C. glabrata , C. parapsilosis, and C. tropicalis both in vitro and in clinical infections as described in INDICATIONS AND USAGE and CLINICAL STUDIES. Because of the potential for reduced susceptibility to anidulafungin, it is recommended that susceptibility be determined by a standardized method. Anidulafungin minimal inhibitory concentrations (MICs) were determined for isolates of Candida spp. obtained during clinical studies using a standardized method. However, no correlation between in vitro activity as determined by this method and clinical outcome was established. Drug Resistance Echinocandin resistance is due to point mutations within the genes (FKS1 and FKS2) encoding for subunits in the glucan synthase enzyme complex. There have been reports of Candida isolates with reduced susceptibility to anidulafungin, suggesting a potential for development of drug resistance. The clinical significance of this observation is not fully understood. Nonclinical Toxicology Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term animal carcinogenicity studies of anidulafungin have not been conducted. Anidulafungin was not genotoxic in the following in vitro studies: bacterial reverse mutation assays, a chromosome aberration assay with Chinese hamster ovary cells, and a forward gene mutation assay with mouse lymphoma cells. Anidulafungin was not genotoxic in mice using the in vivo micronucleus assay. Anidulafungin produced no adverse effects on fertility in male or female rats at intravenous doses of 20 mg/kg/day (equivalent to 2 times the proposed therapeutic maintenance dose of 100 mg/day on the basis of relative body surface area). Animal Toxicology and/or Pharmacology In 3 month studies, liver toxicity, including single cell hepatocellular necrosis, hepatocellular hypertrophy and increased liver weights were observed in monkeys and rats at doses equivalent to 5 6 times human exposure. For both species, hepatocellular hypertrophy was still noted one month after the end of dosing. Clinical Studies Candidemia and Other Candida Infections (Intra-abdominal Abscess and Peritonitis) The safety and efficacy of Eraxis were evaluated in a Phase 3, randomized, double-blind study of patients with candidemia and/or other forms of invasive candidiasis. Patients were randomized to receive once daily IV Eraxis (200 mg loading dose followed by 100 mg maintenance dose) or IV fluconazole (800 mg loading dose followed by 400 mg maintenance dose). Patients were stratified by APACHE II score ( 20 and >20) and the presence or absence of neutropenia. Patients with Candida endocarditis, osteomyelitis or meningitis, or those with infection due to C. krusei, were excluded from the study. Treatment was administered for at least 14 and not more than 42 days. Patients in both study arms were permitted to switch to oral fluconazole after at least 10 days of intravenous therapy, provided that they were able to tolerate oral medication, were afebrile for at least 24 hours, and the last blood cultures were negative for Candida species. Patients who received at least one dose of study medication and who had a positive culture for Candida species from a normally sterile site before entry into the study (modified intent-to-treat [MITT] population) were included in the analysis of global response at the end of IV therapy. A successful global response required clinical cure or improvement (significant, but incomplete resolution of signs and symptoms of the Candida infection and no additional antifungal treatment), and documented or presumed microbiological eradication. Patients with an indeterminate outcome were analyzed as failures in this population. Two hundred and fifty-six patients in the intent-to-treat (ITT) population were randomized and received at least one dose of study medication. In Eraxis-treated patients, the age range was 16 89 years, the gender distribution was 50% male and 50% female, and the race distribution was 71% White, 20% Black/African American, 7% Hispanic, 2% other races. The median duration of IV therapy was 14 and 11 days in the Eraxis and fluconazole arms, respectively. For those who received oral fluconazole, the median duration of oral therapy was 7 days for the Eraxis arm and 5 days for the fluconazole arm. Patient disposition is presented in Table 7. Table 7: Patient Disposition and Reasons for Discontinuation in Candidemia and other Candida Infections Study Eraxis Fluconazole n (%) n (%) Treated patients 131 125 Patients completing study through 6 week follow-up 94 (72) 80 (64) DISCONTINUATIONS FROM STUDY MEDICATION Total discontinued from study medication 34 (26) 48 (38) Discontinued due to adverse events 12 (9) 21 (17) Discontinued due to lack of efficacy 11 (8) 16 (13) Two hundred and forty-five patients (127 Eraxis, 118 fluconazole) met the criteria for inclusion in the MITT population. Of these, 219 patients (116 Eraxis, 103 fluconazole) had candidemia only. Risk factors for candidemia among patients in both treatment arms in this study were: presence of a central venous catheter (78%), receipt of broad-spectrum antibiotics (69%), recent surgery (42%), recent hyperalimentation (25%), and underlying malignancy (22%). The most frequent species isolated at baseline was C. albicans (62%), followed by C. glabrata (20%), C. parapsilosis (12%) and C. tropicalis (11%). The majority (97%) of patients were non-neutropenic (ANC >500) and 81% had APACHE II scores less than or equal to 20. Global success rates in patients with candidemia and other Candida infections are summarized in Table 8. Table 8: Efficacy Analysis: Global Success in patients with Candidemia and other Candida Infections (MITT Population) Time-point Eraxis (N=127) n (%) Fluconazole (N=118) n (%) Treatment Difference * , % (95% C.I.) * Calculated as Eraxis minus fluconazole † 33 patients in each study arm (26% Eraxis and 29% fluconazole-treated) switched to oral fluconazole after the end of IV therapy. ‡ 98.3% confidence intervals, adjusted post hoc for multiple comparisons of secondary time points End of IV Therapy 96 (75.6) 71 (60.2) 15.4 (3.9, 27.0) End of All Therapy † 94 (74.0) 67 (56.8) 17.2 (2.9, 31.6) ‡ 2 Week Follow-up 82 (64.6) 58 (49.2) 15.4 (0.4, 30.4) ‡ 6 Week Follow-up 71 (55.9) 52 (44.1) 11.8 (-3.4, 27.0) ‡ Table 9 presents global response by patients with candidemia or multiple sites of Candida infection and mortality data for the MITT population. Table 9: Global Response and Mortality in Candidemia and other Candida Infections Eraxis Fluconazole Between group difference * (95% CI) * Calculated as Eraxis minus fluconazole No. of MITT patients 127 118 Global Success (MITT) At End Of IV Therapy Candidemia 88/116 (75.9%) 63/103 (61.2%) 14.7 (2.5, 26.9) Neutropenic 1/2 2/4 - Non neutropenic 87/114 (76.3%) 61/99 (61.6%) - Multiple sites Peritoneal fluid/ intra-abdominal abscess 4/6 5/6 - Blood/ peritoneum (intra-abdominal abscess) 2/2 0/2 - Blood /bile - 1/1 - Blood/renal - 1/1 - Pancreas - 0/3 - Pelvic abscess - 1/2 - Pleural fluid 1/1 - - Blood/ pleural fluid 0/1 - - Blood/left thigh lesion biopsy 1/1 - - Total 8/11 (72.7%) 8/15 (53.3%) - Mortality Overall study mortality 29/127 (22.8 %) 37/118 (31.4%) - Mortality during study therapy 10/127 (7.9%) 17/118 (14.4%) - Mortality attributed to Candida 2/127 (1.6%) 5/118 (4.2%) - Esophageal Candidiasis Eraxis was evaluated in a double-blind, double-dummy, randomized Phase 3 study. Three hundred patients received Eraxis (100 mg loading dose IV on Day 1 followed by 50 mg/day IV) and 301 received oral fluconazole (200 mg loading dose on Day 1 followed by 100 mg/day). Treatment duration was 7 days beyond resolution of symptoms for a minimum of 14 and a maximum of 21 days. Of the 442 patients with culture confirmed esophageal candidiasis, most patients (91%) had C. albicans isolated at the baseline. Treatment groups were similar in demographic and other baseline characteristics. In Eraxis-treated patients, the age range was 16 69 years, the gender distribution was 42% male and 58% female, and the race distribution was 15% White, 49% Black/African American, 15% Asian, 0.3 % Hispanic, 21% other races. In this study, of 280 patients tested, 237 (84.6%) tested HIV positive. In both groups the median time to resolution of symptoms was 5 days and the median duration of therapy was 14 days. Efficacy was assessed by endoscopic outcome at end of therapy (EOT). Patients were considered clinically evaluable if they received at least 10 days of therapy, had an EOT assessment with a clinical outcome other than 'indeterminate', had an endoscopy at EOT, and did not have any protocol violations prior to the EOT visit that would affect an assessment of efficacy. An endoscopic success, defined as cure (endoscopic grade of 0 on a 4-point severity scale) or improvement (decrease of one or more grades from baseline), was seen in 225/231 (97.4%) Eraxis-treated patients and 233/236 (98.7%) fluconazole-treated patients (Table 10). The majority of these patients were endoscopic cures (grade=0). Two weeks after completing therapy, the Eraxis group had significantly more endoscopically-documented relapses than the fluconazole group, 120/225 (53.3%) vs. 45/233 (19.3%), respectively (Table 10). Table 10: Endoscopy Results in Patients with Esophageal Candidiasis (Clinically Evaluable Population) * Calculated as Eraxis minus fluconazole Endoscopic Response at End of Therapy Response Eraxis N=231 Fluconazole N=236 Treatment Difference * 95% CI Endoscopic Success, n (%) 225 (97.4) 233 (98.7) -1.3% -3.8%, 1.2% Cure 204 (88.3) 221 (93.6) Improvement 21 (9.1) 12 (5.1) Failure, n (%) 6 (2.6) 3 (1.3) Endoscopic Relapse Rates at Follow-Up, 2 Weeks Post-Treatment Eraxis Fluconazole Treatment Difference * 95% CI Endoscopic Relapse, n/N (%) 120/225 (53.3%) 45/233 (19.3%) 34.0% 25.8%, 42.3% Clinical success (cure or improvement in clinical symptoms including odynophagia/dysphagia and retrosternal pain) occurred in 229/231 (99.1%) of the Eraxis-treated patients and 235/236 (99.6%) of the fluconazole-treated patients at the end of therapy. For patients with C. albicans , microbiological success occurred in 142/162 (87.7%) of the Eraxis-treated group and 157/166 (94.6%) of the fluconazole-treated group at the end of therapy. For patients with Candida species other than C. albicans , success occurred in 10/12 (83.3%) of the Eraxis-treated group and 14/16 (87.5%) of the fluconazole-treated group. How Supplied/Storage and Handling How Supplied Eraxis (anidulafungin) for Injection is supplied in a single-use vial of sterile, lyophilized, preservative-free, powder. Eraxis (anidulafungin) is available in the following packaging configuration: Single-Use Vial of Eraxis 50 mg NDC 0049-0114-28 One - 50 mg vial Single-Use Vial of Eraxis 100 mg NDC 0049-0116-28 One - 100 mg vial Storage Unreconstituted vials Eraxis unreconstituted vials should be stored in a refrigerator at 2 C 8 C (36 F 46 F). Do not freeze. Excursions for 96 hours up to 25ºC (77ºF) are permitted, and the vial can be returned to storage at 2 C 8 C (36 F 46 F). Reconstituted solution Eraxis reconstituted solution can be stored at up to 25 C (77 F) for up to 24 hours. Chemical and physical in-use stability of the reconstituted solution has been demonstrated for 24 hours at 25ºC (77ºF). From a microbiological point of view, following good aseptic practices, the reconstituted solution can be utilized for up to 24 hours when stored at 25ºC. Infusion Solution Eraxis infusion solution can be stored at temperatures up to 25 C (77 F) for up to 48 hours or stored frozen for at least 72 hours. Chemical and physical in-use stability of the infusion solution has been demonstrated for 48 hours at 25ºC (77ºF) or 72 hours when stored frozen. From a microbiological point of view, following good aseptic practices, the infusion solution can be utilized for up to 48 hours from preparation when stored at 25ºC. Patient Counseling Information Hepatic Effects Inform patients about the risk of developing abnormal liver function tests and/or hepatic dysfunction. Advise the patient that liver function tests may be monitored during treatment. Hypersensitivity Inform the patient that anaphylactic reactions, including shock were reported with Eraxis. Inform the patient if these reactions occur, Eraxis may be discontinued and appropriate treatment administered. Inform the patient that Eraxis is also known to cause infusion-related adverse reactions, possibly histamine-mediated. Inform the patient to report symptoms including rash, urticaria, flushing, pruritus, dyspnea, and hypotension to their healthcare provider. Pregnant Women and Nursing Mothers Inform patients that Eraxis has not been studied in pregnant women or nursing mothers so the effects of Eraxis on pregnant women or nursing infants are not known. Instruct patients to tell their healthcare provider if they are pregnant, become pregnant, or are thinking about becoming pregnant. Instruct patients to tell their healthcare provider if they plan to breast-feed their infant. This product's label may have been updated. For current full prescribing information, please visit www.pfizer.com. LAB-0336-9.0 November 2013 PRINCIPAL DISPLAY PANEL - 50 mg Vial Label 1 Sterile Single-use Vial Eraxis (anidulafungin) for Injection 50 mg/vial For Intravenous Infusion Only Pfizer Injectables Distributed by: Roerig Division of Pfizer Inc NY, NY 10017 Rx only PRINCIPAL DISPLAY PANEL - 50 mg Vial Carton NDC 0049-0114-28 Unit Pack Contains: 1 Sterile Single-use Vial Eraxis 50 mg Eraxis (anidulafungin) for Injection 50 mg/vial For Intravenous Infusion Only Store Vial in Refrigerator at 2 - 8 C (36 - 46 F). Do Not Freeze. Reconstitute with Sterile Water for Injection. Pfizer Injectables Distributed by: Roerig Division of Pfizer Inc NY, NY 10017 Rx only PRINCIPAL DISPLAY PANEL - 100 mg Vial Label 1 Sterile Single-use Vial Eraxis (anidulafungin) for Injection 100 mg/vial For Intravenous Infusion Only Pfizer Injectables Distributed by: Roerig Division of Pfizer Inc NY, NY 10017 Rx only PRINCIPAL DISPLAY PANEL - 100 mg Vial Carton NDC 0049-0116-28 Unit Pack Contains: 1 Sterile Single-use Vial Eraxis 100 mg Eraxis (anidulafungin) for Injection 100 mg/vial For Intravenous Infusion Only Store Vial in Refrigerator at 2 - 8 C (36 - 46 F). Do Not Freeze. Reconstitute with Sterile Water for Injection. Pfizer Injectables Distributed by: Roerig Division of Pfizer Inc NY, NY 10017 Rx only Eraxis anidulafungin injection, powder, lyophilized, for solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0049-0114 Route of Administration INTRAVENOUS DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength ANIDULAFUNGIN (ANIDULAFUNGIN) ANIDULAFUNGIN 50 mg in 15 mL Inactive Ingredients Ingredient Name Strength FRUCTOSE 50 mg in 15 mL MANNITOL 250 mg in 15 mL POLYSORBATE 80 125 mg in 15 mL TARTARIC ACID 5.6 mg in 15 mL SODIUM HYDROXIDE HYDROCHLORIC ACID Packaging # Item Code Package Description 1 NDC:0049-0114-28 15 mL in 1 VIAL, SINGLE-USE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021632 02/17/2006 Eraxis anidulafungin injection, powder, lyophilized, for solution Product Information Product Type HUMAN PRESCRIPTION DRUG LABEL Item Code (Source) NDC:0049-0116 Route of Administration INTRAVENOUS DEA Schedule Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength ANIDULAFUNGIN (ANIDULAFUNGIN) ANIDULAFUNGIN 100 mg in 30 mL Inactive Ingredients Ingredient Name Strength FRUCTOSE 100 mg in 30 mL MANNITOL 500 mg in 30 mL POLYSORBATE 80 250 mg in 30 mL TARTARIC ACID 11.2 mg in 30 mL SODIUM HYDROXIDE HYDROCHLORIC ACID Packaging # Item Code Package Description 1 NDC:0049-0116-28 30 mL in 1 VIAL, SINGLE-USE Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date NDA NDA021632 02/17/2006 Labeler - Roerig (829076996) Registrant - Pfizer Inc (113480771) Establishment Name Address ID/FEI Operations Pharmacia and Upjohn Company LLC 618054084 ANALYSIS(0049-0114, 0049-0116), API MANUFACTURE(0049-0114, 0049-0116), LABEL(0049-0114, 0049-0116), MANUFACTURE(0049-0114, 0049-0116), PACK(0049-0114, 0049-0116) Establishment Name Address ID/FEI Operations Eurofins Lancaster Laboratories, Inc 069777290 ANALYSIS(0049-0114, 0049-0116) Establishment Name Address ID/FEI Operations Associates of Cape Cod, Inc. 076574078 ANALYSIS(0049-0114, 0049-0116) Revised: 02/2016 Roerig Next Interactions Print this page Add to My Med List More about Eraxis (anidulafungin) Side Effects During Pregnancy Dosage Information Drug Interactions Support Group Pricing & Coupons En Español 0 Reviews Add your own review/rating Drug class: echinocandins Consumer resources Eraxis Eraxis (Advanced Reading) Professional resources Eraxis (AHFS Monograph) Related treatment guides Candidemia Esophageal Candidiasis> ]} FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only B Pregnancy Category No proven risk in humans N/A CSA Schedule Not a controlled drug Approval History Drug history at FDA Manufacturer Pfizer Inc. Drug Class Echinocandins Related Drugs echinocandins caspofungin , micafungin , Mycamine , Cancidas , anidulafungin Candidemia fluconazole , Diflucan , itraconazole , voriconazole , amphotericin b , Sporanox , posaconazole , caspofungin , micafungin , Mycamine , AmBisome , Noxafil , More... Esophageal Candidiasis fluconazole , Diflucan , itraconazole , voriconazole , amphotericin b , Sporanox , caspofungin , micafungin , Mycamine , Vfend , Cancidas , Onmel , More... Eraxis Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first!} } is legendary
mechanically cleanable Eraxis disregarded
EmoticonEmoticon